Ensign Peak Advisors
DYN icon

Ensign Peak Advisors’s Dyne Therapeutics DYN Stock Holding History

Ensign Peak Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.43M Sell
289,730
-206,860
-42% -$3.85M 0.01% 521
2026
Q1 		$9M Hold
496,590
– – 0.02% 429
2025
Q4 		$9.71M Buy
496,590
+476,440
+2,364% +$9.02M 0.02% 415
2025
Q3 		$255K Sell
20,150
-245,923
-92% -$2.8M ﹤0.01% 1609
2025
Q2 		$2.53M Buy
266,073
+245,923
+1,220% +$2.71M ﹤0.01% 828
2025
Q1 		$211K Sell
20,150
-295,452
-94% -$4.23M ﹤0.01% 1669
2024
Q4 		$7.44M Buy
315,602
+2,850
+0.9% +$84.3K 0.01% 546
2024
Q3 		$11.2M Hold
312,752
– – 0.02% 439
2024
Q2 		$11M Sell
312,752
-298,541
-49% -$8.68M 0.02% 420
2024
Q1 		$17.4M Buy
611,293
+100,000
+20% +$2.26M 0.03% 347
2023
Q4 		$6.8M Hold
511,293
– – 0.01% 553
2023
Q3 		$4.58M Hold
511,293
– – 0.01% 595
2023
Q2 		$5.75M Buy
511,293
+284,667
+126% +$3.36M 0.01% 548
2023
Q1 		$2.61M Buy
226,626
+186,626
+467% +$2.42M 0.01% 742
2022
Q4 		$464K Sell
40,000
-4,270
-10% -$49.4K ﹤0.01% 1636
2022
Q3 		$562K Buy
44,270
+4,270
+11% +$49K ﹤0.01% 1390
2022
Q2 		$275K Hold
40,000
– – ﹤0.01% 1705
2022
Q1 		$386K Hold
40,000
– – ﹤0.01% 1662
2021
Q4 		$476K Hold
40,000
– – ﹤0.01% 1646
2021
Q3 		$650K Hold
40,000
– – ﹤0.01% 1567
2021
Q2 		$842K Hold
40,000
– – ﹤0.01% 1485
2021
Q1 		$621K Hold
40,000
– – ﹤0.01% 1562
2020
Q4 		$840K Hold
40,000
– – ﹤0.01% 1467
2020
Q3 		$808K Buy
+40,000
New +$878K ﹤0.01% 1401

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Ensign Peak Advisors's DYN Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Dyne Therapeutics (DYN) stake by 42% in Q2 2026, selling an estimated $3.85M and leaving 289,730 shares worth $6.43M. The position accounts for 0.01% of the portfolio, ranked #521.

Ensign Peak Advisors first reported a position in DYN in Q3 2020 and has held it in 24 quarters since. The position peaked at $17.4M in Q1 2024. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Ensign Peak Advisors held 289,730 shares of Dyne Therapeutics worth $6.43M as of Q2 2026.
  • Ensign Peak Advisors sold 206,860 Dyne Therapeutics shares in Q2 2026, an estimated $3.85M.
  • Dyne Therapeutics made up 0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #521 holding.
  • Ensign Peak Advisors first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Ensign Peak Advisors's Dyne Therapeutics position peaked at $17.4M in Q1 2024.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.